PEGylation makes F9 suitable for passive targeting due to a prolonged blood circulation profile by evading the immune system thus maximising its accumulation in colon tumour mass and minimising its unnecessary biodistribution to other body organs after i.v. administration. Here, F9 is linked to colonic neoplasm.